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A 47‐year‐old male with no past history developed abdominal distension and fatigue, and was found to have anemia (hemoglobin 7.4 g/dL), thrombocytopenia (platelets 74 × 10^9^/L), and leukocytosis (WBC 33 × 10^9^/L) with 8% circulating blasts. Imaging showed marked hepatosplenomegaly and diffuse bulky lymphadenopathy (Figure [1](#ccr32473-fig-0001){ref-type="fig"}).

![A PET/CT scan showing spleen length of 31 cm, liver length of 26 cm, and diffuse bulky lymphadenopathy](CCR3-7-2274-g001){#ccr32473-fig-0001}

Bone marrow biopsy and clinical presentation were consistent with primary myelofibrosis (Figure [2](#ccr32473-fig-0002){ref-type="fig"}). As lymphadenopathy is rare in PMF, he underwent axillary lymph node biopsy which demonstrated effacement by immature‐appearing cells (Figure [3](#ccr32473-fig-0003){ref-type="fig"}). Flow cytometry showed an immature cell population (CD45 dim) that was negative for CD34, CD56, CD117, and MPO; strongly positive for CD4; and variably positive for CD10, CD33, HLA‐DR, CD68, CD123, and E‐cadherin, consistent with myeloid sarcoma (MS). The patient did not respond to induction chemotherapy with daunorubicin, cytarabine, and cladribine, but lymphadenopathy resolved after three cycles of decitabine and ruxolitinib. He progressed after six cycles, and was transitioned to azacytidine and venetoclax. He proceeded to allogeneic stem cell transplant, but died from veno‐occlusive disease on day +11.

![Bone marrow biopsy with hematoxylin & eosin staining, 10× objective magnification. Bone marrow is hypercellular (90%) with atypical megakaryocytes, fibrosis (MF‐2), and 1% blasts. Molecular testing demonstrated mutations in JAK2(V617F), NRAS(G12D), SETBP1(D868N and D874H), SRSF2(P95L), and TET2(Q916\* and R1516\*). Karyotype was normal on both bone marrow biopsy and lymph node biopsy](CCR3-7-2274-g002){#ccr32473-fig-0002}

![Lymph node biopsy with hematoxylin and eosin staining, 20× objective magnification. This shows an aggregate of small lymphocytes in the lower right representing a residual lymph node follicle; the remainder of the lymph node is effaced by immature cells. Karyotype was normal on both bone marrow biopsy and lymph node biopsy](CCR3-7-2274-g003){#ccr32473-fig-0003}

While MS commonly affects lymph nodes,[1](#ccr32473-bib-0001){ref-type="ref"} it rarely presents with diffuse involvement as in this case. Immunophenotyping is critical in diagnosing MS, as it can be difficult to differentiate from other diagnoses, including lymphoma, using light microscopy.[2](#ccr32473-bib-0002){ref-type="ref"}
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